Is TNDM a Buy? What to Consider in 2026
Short answer
The bull case for Tandem Diabetes Care (TNDM) rests on Recurring supplies and a growing installed base: Tandem ended 2025 with a U.S. FY2025 revenue is ~$1.0 billion worldwide. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Competition is the central risk: Insulet's tubeless Omnipod 5 is the fastest-growing system in the market, Medtronic remains a large incumbent, and newer entrants like Beta Bionics' iLet and Sequel's twiist add pressure, all of which can squeeze Tandem's pricing and pump share. Whether TNDM is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Tandem Diabetes Care designs, makes, and sells insulin pumps for people with diabetes. Its flagship products are the t:slim X2 pump and the much smaller Tandem Mobi system, both running Control-IQ+ automated insulin delivery software that reads data from a continuous glucose monitor (CGM) and automatically adjusts insulin dosing. The business works on a razor-and-blade model: Tandem earns an up-front sale when a customer adopts a pump, then recurring revenue from the disposable cartridges, infusion sets, and other supplies that customer buys for years afterward. Pumps integrate with third-party CGMs from Dexcom (G6/G7) and Abbott (FreeStyle Libre), which Tandem does not make itself. The company shipped its first t:slim pump in 2012 and built its lead through software, releasing Control-IQ automation and then Control-IQ+, which was cleared for commercial use in 2025 and expanded to younger patients and additional indications. The Tandem Mobi, the company's smallest pump, has been ramping in the U.S. and internationally, with Android phone control added in the 2025-2026 window. Tandem competes in a crowded automated insulin delivery market against Insulet's tubeless Omnipod 5, Medtronic's MiniMed 780G, Beta Bionics' iLet, and newer entrant Sequel Medtech's twiist, which launched in 2025. It is also navigating a shift toward a pay-as-you-go (PayGo) pharmacy-channel model that creates near-term pricing headwinds.
What's the case for buying TNDM?
1. Recurring supplies and a growing installed base.
Tandem ended 2025 with a U.S. installed base of roughly 324,000 customers, each generating recurring revenue from pump supplies long after the initial sale. Worldwide sales reached about $1 billion for full-year 2025. This razor-and-blade dynamic gives the business a growing, relatively predictable revenue stream that compounds as more pumps are placed and renewed.
2. Tandem Mobi and Control-IQ+ product cycle.
The miniaturized Tandem Mobi, billed as the world's smallest durable automated insulin delivery system, has been ramping in the U.S. and internationally, with Android phone control added in 2025-2026. Control-IQ+ software was cleared for commercial use in 2025 and broadened to younger patients. These launches are central to keeping Tandem competitive against tubeless and patch-pump rivals.
3. International growth and CGM integrations.
International pump shipments rose to more than 40,000 for full-year 2025, an increasingly important growth lever. Tandem also began the global rollout of t:slim X2 integration with Abbott's FreeStyle Libre 3 Plus sensor, adding to existing Dexcom G6/G7 support. Wider sensor choice can broaden Tandem's addressable customer base across geographies.
4. Turn toward profitability.
Full-year 2025 non-GAAP gross margin was about 54%, with the fourth quarter at roughly 58%, and Q4 2025 adjusted EBITDA was positive at about $32.9 million (11% of sales). For 2026 management guided to gross margins of 56% to 57% and full-year positive adjusted EBITDA of 5% to 6%, though revenue growth is tempered by a $70 million to $80 million pricing headwind from the PayGo transition.
What are the risks to TNDM?
Competition is the central risk: Insulet's tubeless Omnipod 5 is the fastest-growing system in the market, Medtronic remains a large incumbent, and newer entrants like Beta Bionics' iLet and Sequel's twiist add pressure, all of which can squeeze Tandem's pricing and pump share. GLP-1 weight-loss drugs are a structural unknown that management has acknowledged may have weighed on the broader insulin-therapy market since 2023, though the long-term effect on pump demand is unclear. Tandem still posts GAAP net losses (about $204.7 million in 2025) and must execute its PayGo pharmacy-channel transition without losing customers, while reimbursement decisions and product execution on Mobi and new integrations all carry uncertainty.
How is TNDM valued? (as of FY2025 results (reported February 2026) and Q1 2026)
- FY2025 revenue: ~$1.0 billion worldwide
- Pump shipments: International >40,000 for FY2025; ~29,000 worldwide in Q1 2026
- U.S. installed base: ~324,000 customers (12/31/25)
- Gross margin (non-GAAP): ~54% FY2025; ~58% Q4 2025
- Adjusted EBITDA: -$46.1M FY2025 (-5%); +$32.9M in Q4 2025
- GAAP net loss: ~$204.7 million (FY2025)
- Market cap: ~$1.1-1.3 billion (2026)
Tandem is best read as a growth medtech rather than a mature, profitable company. The model is razor-and-blade: pumps are sold (sometimes at thin margin) to build an installed base, and the recurring supplies that base buys over the following years drive higher-margin revenue. Heavy spending on research, sales, and manufacturing scale is why the company has not been consistently profitable on a GAAP basis even at roughly $1 billion in sales, so investors tend to watch pump shipments, installed-base growth, gross margin, and the path to positive adjusted EBITDA rather than a simple P/E ratio.
How do you decide if TNDM is a buy?
Rather than asking whether TNDM is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold TNDM indirectly through an index or sector ETF before adding more.
For the full picture, see the TNDM stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about TNDM against your real portfolio and see your actual exposure before deciding.
The bottom line on TNDM
The bottom line: Tandem Diabetes Care's story right now is Recurring supplies and a growing installed base, with fy2025 revenue at ~$1.0 billion worldwide. If you believe that narrative continues, the call is about sizing TNDM sensibly and checking overlap with what you own; if you doubt it (the risk: competition is the central risk: Insulet's tubeless Omnipod 5 is the fastest-growing system in the market, Medtronic remains a large incumbent, and newer entrants like Beta Bionics' iLet and Sequel's twiist add pressure, all of which can squeeze Tandem's pricing and pump share.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around TNDM with Walnut
Use Tandem Diabetes Care as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is TNDM a good stock to buy right now?
+
The case for Tandem Diabetes Care right now is Recurring supplies and a growing installed base, with fy2025 revenue at ~$1.0 billion worldwide. If you believe that thesis holds, TNDM is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is competition is the central risk: Insulet's tubeless Omnipod 5 is the fastest-growing system in the market, Medtronic remains a large incumbent, and newer entrants like Beta Bionics' iLet and Sequel's twiist add pressure, all of which can squeeze Tandem's pricing and pump share. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Tandem Diabetes Care do?
+
Maker of insulin pumps (t:slim X2 and the miniaturized Mobi) with Control-IQ automated insulin delivery, a growth medtech nearing $1 billion in sales while working toward consistent profitability against rivals like Insulet and Medtronic.
What are the main risks of TNDM?
+
Competition is the central risk: Insulet's tubeless Omnipod 5 is the fastest-growing system in the market, Medtronic remains a large incumbent, and newer entrants like Beta Bionics' iLet and Sequel's twiist add pressure, all of which can squeeze Tandem's pricing and pump share. GLP-1 weight-loss drugs are a structural unknown that management has acknowledged may have weighed on the broader insulin-therapy market since 2023, though the long-term effect on pump demand is unclear. Tandem still posts GAAP net losses (about $204.7 million in 2025) and must execute its PayGo pharmacy-channel transition without losing customers, while reimbursement decisions and product execution on Mobi and new integrations all carry uncertainty.
What does Tandem Diabetes Care do?
+
Tandem Diabetes Care makes insulin pumps for people with diabetes, led by the t:slim X2 pump and the miniaturized Tandem Mobi system. Both run its Control-IQ+ automated insulin delivery software, which uses data from a continuous glucose monitor to adjust insulin automatically. Tandem earns money from selling pumps and, over time, from the recurring disposable supplies those pumps require.
Does TNDM pay a dividend?
+
No. Tandem Diabetes Care does not pay a dividend. As a growth-stage medical-device company still working toward consistent profitability, it reinvests cash into research, product launches, and scaling its business, so any shareholder return would come from share-price changes rather than dividend income.
Is TNDM a good stock?
+
This is descriptive, not advice. The bull case is a growing installed base of around 324,000 U.S. customers, recurring supply revenue, new products like Mobi and Control-IQ+, and a 2026 turn toward positive adjusted EBITDA. The bear case is heavy competition from Omnipod and Medtronic, uncertain GLP-1 drug effects on pump demand, and continuing GAAP net losses. Whether it fits you depends on your own goals and risk tolerance.
Is TNDM a good stock to buy right now?
+
This is informational, not a recommendation. TNDM tends to be volatile and competition-sensitive, reacting to pump shipment trends, product ramps, gross-margin progress, and news about rivals or GLP-1 drugs. Some investors focus on its path to profitability and installed-base growth, while others worry about market share and the PayGo pricing transition. Walnut provides information, not investment advice.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell TNDM; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.